REGENXBIO INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.08 USD | +2.33% |
|
-1.88% | -21.56% |
Financials (USD)
| Sales 2024 * | 98.44M | Sales 2025 * | 245M | Capitalization | 694M |
|---|---|---|---|---|---|
| Net income 2024 * | -231M | Net income 2025 * | -113M | EV / Sales 2024 * | 6.01 x |
| Net cash position 2024 * | 102M | Net cash position 2025 * | 157M | EV / Sales 2025 * | 2.19 x |
| P/E ratio 2024 * |
-2.84
x | P/E ratio 2025 * |
-8.03
x | Employees | 344 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.81% |
More Fundamentals
* Assessed data
More news
Latest transcript on REGENXBIO Inc.
More recommendations
More press releases
| 1 day | +2.33% | ||
| 1 week | -1.88% | ||
| Current month | -1.88% | ||
| 1 month | -16.98% | ||
| 3 months | -39.39% | ||
| 6 months | -31.65% | ||
| Current year | -21.56% |
1 week
13.73
14.95
1 month
13.7316.85
Current year
11.8328.80
1 year
11.8328.80
3 years
11.8346.46
5 years
11.8355.23
10 years
7.0785.10
| Managers | Title | Age | Since |
|---|---|---|---|
Kenneth Mills
FOU | Founder | 49 | 08-07-15 |
Vit Vasista
DFI | Director of Finance/CFO | 56 | 09-07-31 |
| Chief Tech/Sci/R&D Officer | - | 15-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
George Migausky
BRD | Director/Board Member | 69 | 21-09-02 |
David Stump
BRD | Director/Board Member | 74 | 15-10-14 |
| Director/Board Member | 71 | 15-04-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.76% | 15 M€ | -3.61% | ||
| 0.25% | 26 M€ | -4.59% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 14.08 | +2.33% | 329,467 |
| 24-06-06 | 13.76 | -5.23% | 397,412 |
| 24-06-05 | 14.52 | +1.40% | 258,573 |
| 24-06-04 | 14.32 | -2.98% | 303,022 |
| 24-06-03 | 14.76 | +2.86% | 355,505 |
Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT
More quotes
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three areas: retinal, neuromuscular and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202 and RGX-121. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Calendar
2024-06-12
- Goldman Sachs Global Healthcare Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
14.08
USD
Average target price
38.92
USD
Spread / Average Target
+176.40%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -21.56% | 694M | |
| +18.72% | 125B | |
| +14.19% | 108B | |
| -4.93% | 24.21B | |
| +3.23% | 22.78B | |
| -10.44% | 17.96B | |
| -41.74% | 16.43B | |
| -13.31% | 16.37B | |
| +2.44% | 13.58B | |
| +27.89% | 11.66B |
- Stock Market
- Equities
- RGNX Stock
